Welcome to Oncternal Therapeutics


Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments to treat hematological malignancies and prostate cancer across multiple modalities.

Recent News

We are enrolling patients:

With Relapsed or Refractory B-Cell Malignancies for a Phase 1/2 study of ONCT-808, our ROR1-Targeting Autologous Cell Therapy (NCT05588440)

Participate in Our Trials